Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension
- PMID: 3225688
Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension
Abstract
Blood pressure, forearm arterial haemodynamics and echocardiographic parameters were studied in patients with sustained essential hypertension before and after administration of the angiotensin converting enzyme (ACE) inhibitor perindopril for 1 year. Perindopril significantly reduced blood pressure and at the same time increased brachial artery blood flow, diameter and compliance. As part of the haemodynamic investigation, a 5-min period of wrist occlusion was performed. Blood flow velocity decreased significantly to the same extent with perindopril and with placebo, but the corresponding reductions in arterial diameter were smaller with perindopril than with placebo, indicating that the increase in diameter following perindopril could not be explained solely on the basis of a flow-dependent dilation. After 3 months, treatment was stopped for 4 weeks. Blood pressure and forearm arterial haemodynamics returned towards baseline values. However, cardiac mass, which was significantly decreased after perindopril administration, remained decreased 4 weeks after cessation of treatment. In seven responder patients, perindopril was continued as sole therapy for 8 months. Arterial compliance remained elevated and cardiac mass diminished. The study showed that the arterial changes caused by perindopril involved a drug-related relaxation of arterial smooth muscle and that there was a differential response in cardiac and arterial changes following long-term treatment.
Similar articles
-
Haemodynamic effects of perindopril in essential hypertension.J Hum Hypertens. 1990 Oct;4 Suppl 4:35-43; discussion 44. J Hum Hypertens. 1990. PMID: 2283652 Clinical Trial.
-
[Cardiac hypertrophy and arterial compliance after antihypertensive treatment].Arch Mal Coeur Vaiss. 1991 Dec;84 Spec No 4:79-83. Arch Mal Coeur Vaiss. 1991. PMID: 1838923 Review. French.
-
Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension.Circulation. 1988 Oct;78(4):941-50. doi: 10.1161/01.cir.78.4.941. Circulation. 1988. PMID: 2971473 Clinical Trial.
-
Peripheral haemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers.J Hypertens Suppl. 1988 Dec;6(3):S41-3. J Hypertens Suppl. 1988. PMID: 2852235
-
Cardiac hypertrophy and arterial compliance following drug treatment in hypertension.J Cardiovasc Pharmacol. 1991;18 Suppl 7:S37-9. J Cardiovasc Pharmacol. 1991. PMID: 1725199 Review.
Cited by
-
Choosing the right ACE inhibitor. A guide to selection.Drugs. 1995 Apr;49(4):516-35. doi: 10.2165/00003495-199549040-00003. Drugs. 1995. PMID: 7789286 Review.
-
Perindopril. A review of its pharmacokinetics and clinical pharmacology.Drugs. 1990;39 Suppl 1:49-63. doi: 10.2165/00003495-199000391-00009. Drugs. 1990. PMID: 2407493 Review.
-
Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs. 1991 Jul;42(1):90-114. doi: 10.2165/00003495-199142010-00006. Drugs. 1991. PMID: 1718688 Review.
-
Effects of the single and repeated administration of benazepril on systemic and forearm circulation and cardiac function in hypertensive patients.Cardiovasc Drugs Ther. 1993 Apr;7(2):211-6. doi: 10.1007/BF00878510. Cardiovasc Drugs Ther. 1993. PMID: 8357774 Clinical Trial.
-
Effect of perindopril on pulse-wave velocity and endothelin-1 in black hypertensive patients.Cardiovasc J Afr. 2012 Aug;23(7):396-9. doi: 10.5830/CVJA-2012-043. Cardiovasc J Afr. 2012. PMID: 22914998 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous